Patents by Inventor Holly Prentice

Holly Prentice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CELL CULTURE PROCESS
    Publication number: 20260337654
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: July 1, 2026
    Publication date: October 29, 2026
    Inventor: Holly Prentice
  • CELL CULTURE PROCESS
    Publication number: 20260337653
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: July 1, 2026
    Publication date: October 29, 2026
    Inventor: Holly Prentice
  • CELL CULTURE PROCESS
    Publication number: 20260327669
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: July 1, 2026
    Publication date: October 22, 2026
    Inventor: Holly Prentice
  • CELL CULTURE PROCESS
    Publication number: 20260327670
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: July 1, 2026
    Publication date: October 22, 2026
    Inventor: Holly Prentice
  • CELL CULTURE PROCESS
    Publication number: 20260327667
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: July 1, 2026
    Publication date: October 22, 2026
    Inventor: Holly Prentice
  • CELL CULTURE PROCESS
    Publication number: 20260327668
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: July 1, 2026
    Publication date: October 22, 2026
    Inventor: Holly Prentice
  • CELL CULTURE PROCESS
    Publication number: 20260258468
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: April 1, 2026
    Publication date: September 3, 2026
    Inventor: Holly Prentice
  • CELL CULTURE PROCESS
    Publication number: 20260234687
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: April 1, 2026
    Publication date: August 13, 2026
    Inventor: Holly Prentice
  • CELL CULTURE PROCESS
    Publication number: 20250115940
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: October 16, 2024
    Publication date: April 10, 2025
    Inventor: Holly Prentice
  • Cell culture process
    Patent number: 12139735
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: November 12, 2024
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • CELL CULTURE PROCESS
    Publication number: 20210246477
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: September 25, 2020
    Publication date: August 12, 2021
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Cell culture process
    Patent number: 10584365
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: March 10, 2020
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventor: Holly Prentice
  • Methods of cell culture
    Patent number: 10144944
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: December 4, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • CELL CULTURE PROCESS
    Publication number: 20180187230
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: January 29, 2018
    Publication date: July 5, 2018
    Inventor: Holly Prentice
  • Methods of cell culture
    Patent number: 9926583
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 27, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Cell culture process
    Patent number: 9914951
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 13, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • METHODS OF CELL CULTURE
    Publication number: 20170233782
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using ammonium and/or lysine, are described.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 17, 2017
    Inventors: Brian Edward Collins, Holly Prentice, Brett Belongia, Rasheed Tijani
  • METHODS OF CELL CULTURE
    Publication number: 20170226553
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Application
    Filed: April 25, 2017
    Publication date: August 10, 2017
    Inventor: Holly Prentice
  • METHODS OF CELL CULTURE
    Publication number: 20170211114
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Application
    Filed: October 5, 2016
    Publication date: July 27, 2017
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Methods of cell culture
    Patent number: 9677105
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using ammonium and/or lysine, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 13, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Brian Edward Collins, Holly Prentice, Brett Belongia, Rasheed Tijani